Scancell - Final Results for the year ended 30 April 2017


  • Strong survival data for patients with Stage III/IV malignant melanoma on SCIB1 Phase 1/2 clinical trial
    • 18 of 20 patients with resected disease remain alive, survival well beyond established norms
    • Of the 16 resected patients who received a 2-4mg dose of SCIB1, seven patients have now survived for five years since starting treatment and only six patients have had recurrence of their disease, of whom, two have died
    • Final Clinical Study Report completed in December 2016 which included safety, immunology and clinical data from patients with Stage III/IV melanoma up to 29 October 2015
  • Investigational New Drug (IND) application for SCIB1 Phase 2 checkpoint inhibitor combination study expected to be submitted in early 2018, with patient enrolment planned for 2018
  • Continued good progress in development of Modi-1, our lead product from the Moditope® platform
    • Ultra-efficient linked adjuvant identified that works at up to 100-fold lower doses than could be achieved previously
    • Aiming to file a Clinical Trial Application (CTA) in the UK for the planned Phase 1/2 clinical trial in breast cancer, ovarian cancer and sarcoma in 2018
    • Early feedback from the European Patent Office suggests that broad patent claims for the Moditope® platform may be allowable
  • Opening of new offices in San Diego to support the Company’s US growth plans, and in Oxford for its UK corporate and development activities
  • Loss for year of £3.5m (2016: loss £2.6m)
  • Group cash balance at 30 April 2017 was £2.7m (30 April 2016: £6.5m) 

You can download the full presss release below:

More within